INTEROFFICE MEMORANDUM TO: CARL RAUSCH‚ CEO‚ BIOPURE FROM: XXXXXXXXXX‚ MARKETING ANALYST‚ BIOPURE SUBJECT: OXYGLOBIN LAUNCH DATE: 50 4/22/2010 This memorandum is to propose that Biopure prepare to launch Oxyglobin as quickly as possible. The product should be priced at approximately $150 per unit and be advertised and distributed to emergency care veterinarians for use in dogs. Significant efforts need to be made in trade publications to educate veterinarians in this
Premium Blood transfusion Blood Marketing
scenarios of Biopure’s products launching and provides marketing plan of the recommended one. The study shows that Biopure should immediately launch Oxyglobin rather than wait for Hemopure’s FDA Approval then launch both products simultaneously. The proposed price for Oxyglobin is $300 per unit with promotion campaign from time to time. With this set price of immediate launch‚ Biopure will reach breakeven point for Oxyglobin in year 2000 with the amount of 2.13 million USD. Targeting market for Oxyglobin
Free Blood Blood transfusion
Biopure Corporation: Case Write-Up Problem Definition In February 1998 Biopure Corporation faced a difficult decision regarding the launch of its newly developed “blood substitute” products. Biopure had developed “Hemopure”‚ a blood substitute for humans‚ and an ancillary product “Oxyglobin” for the veterinary market1. Hemopure was still in the process of gaining Federal Drug Administration (FDA) approval ‚ while Oxyglobin had already been approved and was ready to be launched1. FDA approval was
Premium Blood Blood transfusion Pricing
BioPure Corporation‚ which was founded in 1984 by entrepreneurs Carl Rausch and David Judelson‚ is a privately owned biopharmaceutical firm specializing in the ultra purification of proteins for human and veterinary use. In 1998 Biopure pioneered the development of oxygen therapeutics using "Hemoglobin"‚ a new class of pharmaceuticals that are intravenously administered to deliver oxygen to the body’s tissues. Biopure’s two products‚ Hemopure for human use‚ and Oxyglobin for animal veterinary use
Free Blood Blood transfusion Blood bank
Carl Rausch FROM: RE: Biopure Market Analysis DATE: Oct 31‚ 2013 Deciding whether to go into the veterinary blood market now or not is a critical decision to Biopure right now. To maximize the profits and capture the valuable opportunity‚ Biopure is recommended to step into the marketplace and be the first to offer Oxyglobin‚ blood substitute for the animal market. Pioneering the veterinary blood market is expected to generate gross profits of $26.55 miilion to Biopure annually‚ with a breakeven
Premium Blood transfusion Blood
Sep 19 Student Name: Miao Wang Net ID: mxw142330 Case Study 1 Biopure Case Questions: 1. Hemopure: a. Identify relevant market segments and speculate whether the product is valuable to each segment at the suggested prices ($600-$800) As the case said the Biopure in human market‚ sometime the Hemopure could be $600-$800 per unit‚ which is very higher price than the Oxyglobin. This high price product which relevant market segments should be taken this price level ‚ following the attach Exhibit
Free Blood Red blood cell Blood transfusion
Estimated Market Demand for Oxyglobin 13 Exhibit 3: Estimation of veterinary Market and per year 14 Exhibit 4: Financial Projections – Sensitivity Analysis 15 Executive Summary In 1998‚ Biopure Corporation is one of the three legitimate contenders in the emerging field of “blood substitutes”. Biopure has invested $200M on the R&D on blood substitutes in the past with its primary goal being the development of a human blood substitute ( Hemopure) but Its entry into animal market (Oxyglobin) had
Premium Blood Blood transfusion
Biopure Market Potential Exercise Suggested Solution Question 1) How would you revise the market potential for Hemopure? The best four-segment solution to the usage problem includes these categories: elective surgery; emergency surgery; in field trauma; and chronic anemia. Current Usage Change Potential Usage Trauma (in field) 200‚000 *10 2‚000‚000 Currently only 10% of trauma cases get blood transfusions in the field. With better storage potential and no need for blood
Free Blood Blood transfusion Surgery
Marketing Management – Assignment No. 2 Topic – Product Pricing (Biopure Case) CASE ANALYSIS for Biopure with respect to Pricing of Oxyglobin Our group analyzed the case and concluded that price of oxyglobin should be determined on perceived value approach. We calculated perceived value from case data and arrived at a price of $181. We are planning to launch it at a price of $175 to Vet so that there is some customer incentive to purchase and at same time‚ there is minimum ‘money left
Premium Price Blood Pricing
Biopure Corporation have two new products that are Oxyglobin and Hemopure. Oxyglobin is the first blood substitute for the veterinary market and is ready for launch. Hemopure is another new blood substitute for the human market and will take two years to launch. Ted Jacobs‚ VP (Human Clinical Trials)‚ is concerned about creating an unrealistic price expectation for Hemopure by marketing Oxyglobin before Hemopure. Whereas‚ Andy Wright‚ VP (Veterinary Products)‚ believes that selling Oxyglobin has
Free Blood Blood transfusion Marketing